InSilico Medicine Cayman TopCo (FRA:O15) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O15 InSilico Medicine Cayman TopCo FRA:O15
20 GF Score
Price €5.25
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo ROE % Adjusted to Book Value?

InSilico Medicine Cayman TopCo FRA:O15 +3.96% 20 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

InSilico Medicine Cayman TopCo's ROE % for the quarter that ended in Dec. 2025 was 0.00%. InSilico Medicine Cayman TopCo's PB Ratio for the quarter that ended in Dec. 2025 was N/A. InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.

InSilico Medicine Cayman TopCo ROE % Adjusted to Book Value Related Terms

InSilico Medicine Cayman TopCo ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo ROE % Adjusted to Book Value Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00

InSilico Medicine Cayman TopCo Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial 0.00 Negative Equity 0.00 0.00 0.00

FRA:O15 vs MSFT, ORCL, PLTR: ROE % Adjusted to Book Value Comparison

For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InSilico Medicine Cayman TopCo ROE % Adjusted to Book Value vs Software Industry

For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value falls into.


FRA:O15
20GF Score
InSilico Medicine Cayman TopCo FRA:O15
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo ROE % Adjusted to Book Value Calculation

InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
InSilico Medicine Cayman TopCo (FRA:O15) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value too high?
InSilico Medicine Cayman TopCo's current ROE % Adjusted to Book Value is 0.00%. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value compare to MSFT and ORCL?
InSilico Medicine Cayman TopCo's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Software company?
A good ROE % Adjusted to Book Value depends on the Software industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Other Exchanges 03696:Hong Kong
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score

Get the complete analysis for FRA:O15

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price